Two treatments with fundamentally different goals

If you have been told you have a cartilage lesion in your knee and are weighing injection options, the most important thing to establish first is that ChondroFiller® and hyaluronic acid (HA) are not competing versions of the same treatment — they address different problems in the same joint.

ChondroFiller® is a collagen scaffold: placed under ultrasound guidance into a focal cartilage defect, it physically fills the gap and recruits the patient's own cells to support tissue repair through a process called acellular matrix-induced chondrogenesis. HA viscosupplementation works differently — injected into the joint, it restores lubrication, reduces friction, and eases pain, but it does not reconstitute the cartilage surface.

A patient with a discrete full-thickness defect and a patient with diffuse osteoarthritic wear are starting from different places. Selecting a symptomatic therapy when a structural defect is the underlying issue can leave that defect untreated and potentially progressing over time — cartilage lesions exceeding roughly 1 cm in size may worsen without structural intervention.

The two approaches are not mutually exclusive, however. HA may play a supporting role — managing symptoms or improving the joint environment — alongside a structural treatment like ChondroFiller®, depending on the clinical picture. The right question is which problem is actually present.

Why focal cartilage defects rarely heal on their own

Cartilage draws its nutrients from the synovial fluid that bathes it, not from a blood supply — there are no vessels running through the tissue itself. In most parts of the body, an injury triggers a vascular response: vessels dilate, repair cells arrive, and healing begins. Articular cartilage has no equivalent mechanism. When a full-thickness defect forms, the gap simply persists.

ICRS grade III and IV lesions — where cartilage loss reaches or approaches the subchondral bone — are particularly exposed to this biological dead end. Rather than stabilising, these defects tend to enlarge under the mechanical load of daily movement. In younger, active patients, a lesion at or above approximately 1 cm in size carries a meaningful risk of spreading into the surrounding cartilage and eventually contributing to more diffuse osteoarthritic change if the structural problem goes unaddressed.

Understanding this matters when comparing treatment categories. A lubricant or pain-modulating injection can improve how a joint feels without altering what is happening at the surface of the defect. A collagen scaffold works on a different principle entirely: it physically occupies the lesion and provides a matrix that the body's own cells can migrate into — targeting the structural gap, not only the symptom. That biological gap is what motivates the scaffold category as a distinct approach.

How ChondroFiller works and what the evidence shows

ChondroFiller® liquid is a CE-marked Class III medical device — an acellular, injectable Type I collagen hydrogel. After image-guided placement into the defect site in an outpatient setting, the material gels in situ, creating a three-dimensional scaffold that acts as a chemotactic matrix: it draws the patient's own progenitor cells in from the surrounding synovium and subchondral bone. Those recruited cells are the engine of repair; the scaffold itself contains no donor cells. This process — acellular matrix-induced chondrogenesis — supports the body's own repair mechanisms rather than delivering a ready-made tissue.

The device is indicated for focal cartilage defects up to 6 cm², a broader range than microfracture, which is typically limited to lesions under 2–4 cm².

What the clinical evidence shows

Across four knee-specific clinical studies, ChondroFiller® liquid produced a mean IKDC score improvement of approximately 30 points — consistently above the 16.7-point threshold regarded as the minimum clinically important difference. In practical terms, a 30-point IKDC gain typically represents a meaningful return of function: patients moving from restricted activity and persistent discomfort toward near-normal daily use. The prospective Jerosch et al. post-market clinical follow-up study provides the most durable data point, with a 32.4-point IKDC gain sustained and slightly increasing at three years, reaching a mean score of 80.

Structural repair quality is documented by MOCART MRI scoring — a measure of defect fill, surface congruity, and tissue integration. Scores of 81.6 to 84.3 at 12 months indicate greater than 80% defect filling and good integration with the surrounding native cartilage. Progressive maturation is visible on imaging: MOCART rises from 65.3 at four weeks to 81.6 at one year, suggesting the scaffold continues to consolidate over time.

The reported complication rate is approximately 0%, with reoperation at 3–8% — lower than the figures associated with microfracture (up to 41%) or ACI/MACI (up to 37%) in the comparative literature. It is worth noting that the available clinical evidence is largely manufacturer-sponsored; independent long-term comparative trials have not yet been published.

What hyaluronic acid does in the knee joint

Injected directly into the knee joint, hyaluronic acid works by supplementing the synovial fluid that normally lubricates and cushions the articular surfaces. In osteoarthritic joints, synovial HA concentration and molecular weight both decline, reducing the fluid's viscoelastic properties; an intra-articular injection restores that viscosity, lowers friction between the cartilage surfaces, and appears to modulate pain signalling within the joint — effects that typically persist for several months per treatment course.

That mechanism translates into a well-documented symptomatic benefit in knee osteoarthritis. The Cochrane 2006 systematic review on viscosupplementation found statistically significant improvements in pain and function compared with placebo. A large U.S. Health Claims Database analysis (Altman et al., PLoS One 2015) extended that picture, associating HA injection with meaningful delay of total knee replacement surgery — framing the benefit as extending beyond short-term pain relief toward possible slowing of the clinical trajectory. Guideline opinion on that evidence, however, is split: OARSI offers conditional support for viscosupplementation; AAOS and ACR are more sceptical, citing modest effect sizes and considerable heterogeneity across trials. Evidence generally favours selection of early-to-moderate OA patients over those with end-stage (Kellgren-Lawrence grade IV) disease.

Its primary licensed indication is symptomatic osteoarthritis and broader joint degeneration rather than discrete focal full-thickness defects — patient selection is typically guided by physical examination and imaging confirming an OA pattern.

Where a patient presents with both a focal lesion and background osteoarthritic change — a combination that is common in clinical practice — HA may serve a supporting role alongside scaffold treatment, addressing the wider symptomatic burden rather than the structural defect itself.

Matching the treatment to the right patient

Three broad clinical pictures help clarify where each treatment sits.

Focal defect, no significant background OA. A younger or active patient whose MRI reveals a discrete, full-thickness chondral lesion — typically from a previous injury or osteochondritis dissecans — is the primary candidate for a scaffold-based approach. The clinical priority is structural: filling the defect and supporting the body's own repair processes before the lesion enlarges and accelerates joint degeneration.

Diffuse osteoarthritic change, no discrete focal lesion. Where imaging shows generalised cartilage thinning across a compartment rather than a contained defect, restoring lubrication and reducing pain is the realistic clinical goal. This is the established territory for HA viscosupplementation — managing symptoms and, in some patients, potentially delaying the need for further intervention.

Both a focal lesion and background OA. This overlap is common and does not force an either/or decision. Scaffold treatment can address the structural defect while HA, where clinically appropriate, targets the surrounding symptomatic joint environment — the two mechanisms work on different problems and are not redundant when used together.

No randomised controlled trial has directly compared ChondroFiller® with HA in focal defect patients; these are not interchangeable alternatives and no head-to-head evidence exists to rank them against each other.

The practical first step is MRI with dedicated cartilage evaluation. Before any treatment discussion, the most useful question to put to a specialist is whether the scan shows a contained focal defect or generalised cartilage loss — because that distinction, more than any symptom score, determines which pathway is clinically appropriate.

Getting a proper knee cartilage assessment

Choosing between a structural and a symptomatic pathway depends on what the imaging actually shows — something a symptom history alone cannot resolve. MRI with dedicated cartilage sequences, including T2 mapping and cartilage segmentation, can distinguish a contained focal full-thickness defect from generalised OA-pattern thinning across a compartment. That distinction is what makes treatment selection defensible: the same symptoms can arise from two very different underlying pictures, and the appropriate injection pathway differs accordingly.

For patients who want that level of detail evaluated without a GP referral or a lengthy wait, Lincolnshire Knee — part of the MSK Doctors group — offers consultant-led assessments supported by onMRI™ AI-assisted knee MRI analysis at clinics in Sleaford NG34 and Grantham NG31. A discussion of whether an injectable collagen scaffold, viscosupplementation, or another option is appropriate can follow within the same pathway.

Book an assessment at lincolnshireknee.co.uk.

1. [1] Hyaluronic acid. https://en.wikipedia.org/?curid=1241101 https://en.wikipedia.org/?curid=1241101
2. [2] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351
3. [3] Hyaline cartilage. https://en.wikipedia.org/?curid=1130627 https://en.wikipedia.org/?curid=1130627